Title:
COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES
Document Type and Number:
WIPO Patent Application WO/2019/233440
Kind Code:
A1
Abstract:
Disclosed are compounds for the treatment or prevention of liver diseases, which are compounds represented by the general formula (I) or (II), optical isomers or pharmaceutically acceptable salts thereof that can be applied to the preparation of drugs for treating or preventing liver diseases.
More Like This:
Inventors:
SHI DONGFANG (CN)
FU CHANGJIN (CN)
CHENG XI (CN)
GONG WEIWEI (CN)
GU JIE (CN)
LI PENGFEI (CN)
ZHANG MIN (CN)
YANG YAN (CN)
JIN WENQING (CN)
FU CHANGJIN (CN)
CHENG XI (CN)
GONG WEIWEI (CN)
GU JIE (CN)
LI PENGFEI (CN)
ZHANG MIN (CN)
YANG YAN (CN)
JIN WENQING (CN)
Application Number:
PCT/CN2019/090135
Publication Date:
December 12, 2019
Filing Date:
June 05, 2019
Export Citation:
Assignee:
JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D407/04; A61K31/357; A61P1/16; A61P37/02; A61P37/08
Foreign References:
| US20020193424A1 | 2002-12-19 | |||
| CN1990485A | 2007-07-04 | |||
| CN103450165A | 2013-12-18 | |||
| CN103113359A | 2013-05-22 | |||
| CN101781292A | 2010-07-21 | |||
| CN102066364A | 2011-05-18 | |||
| CN104447717A | 2015-03-25 |
Other References:
GAZAK RADEK ET AL.: "Molecular mechanisms of silybin and 2, 3-dehydrosilybin antiradical activity-role of individual hydroxyl groups", FREE RADICAL BIOLOGY & MEDICINE, vol. 46, no. 6, 6 December 2008 (2008-12-06), pages 745 - 758, XP025962324, ISSN: 0891-5849, DOI: 10.1016/j.freeradbiomed.2008.11.016
FATTY LIVER AND ALCOHOLIC LIVER DISEASE GROUPS OF BRANCH OF HEPATOLOGY OF CHINESE MEDICAL ASSOCIATION: "Guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease", CHINESE JOURNAL OF HEPATOLOGY, vol. 14, 2006, pages 161 - 163
N. BELEMETSN. KOBYLIAKO. VIRCHENKO ET AL.: "Effects of polyphenol compounds melanin on NAFLD/NASH prevention", BIOMEDICINE AND PHARMACOTHERAPY, vol. 88, 2017, pages 267 - 276
N. KOBYLIAKL. ABENAVOLI: "The role of liver biopsy to assess non-alcoholic fatty liver disease", REVIEWS ON RECENT CLINICAL TRIALS, vol. 9, 2014, pages 159 - 169
G. MUSSOR. GAMBINOM. CASSADER ET AL.: "Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity", ANNALS OF MEDINCINE, vol. 43, 2011, pages 617 - 649, XP008166262, DOI: 10.3109/07853890.2010.518623
C. P. DAYO. F. W. JAMES: "Steatohepatitis: A tale of two ''hits", GASTROENTEROLOGY, vol. 114, no. 4, 1998, pages 842 - 845, XP005138793, DOI: 10.1016/S0016-5085(98)70599-2
C. POSTICJ. GIRARD: "Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 118, no. 3, 2008, pages 829 - 838, XP055580320, DOI: 10.1172/JCI34275
PZ LIK. HEJZ LI ET AL.: "The role of kupffer cells in hepatic diseases", MOLECULAR IMMUNOLOGY, vol. 85, 2017, pages 222 - 229, XP029972496, DOI: 10.1016/j.molimm.2017.02.018
R. SAFADIFM KONIKOFFM. MAHAMID ET AL.: "The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, no. 12, 2014, pages 2085 - 2091
PF SURAI.: "Silymarin as a natural antioxidant: an overview of the current evidence and perspectives", ANTIOXIDANTS (BASEL, vol. 4, 2015, pages 204 - 247, XP009502578, DOI: 10.3390/antiox4010204
A. FEDERICOM. DALLIOC. LOGUERCIO: "Silymarin/silybin and chronic liver disease: a marriage of many years", MOLECULES, vol. 22, 2017, pages 2
S. CLICHICID. OLTEANUA. FILIP ET AL.: "Beneficial effects of silymarin after the discontinuation of CC14-induced liver fibrosis", JOURNAL OF MEDICINAL FOOD, vol. 19, 2016, pages 789 - 797
ZHONGXIN LIU: "The efficacy of silymarin combined with pioglitazone in the treatment of 76 subjects of non-alcoholic fatty liver disease", CHINESE JOURNAL OF CLINICAL GASTROENTEROLOGY, vol. 24, no. 5, 2012, pages 288 - 290
SHELING LU: "Silymarin combined with metformin in the treatment of non-alcoholic fatty liver disease", JOURNAL OF MEDICAL FORUM, vol. 37, no. 4, 2016, pages 153 - 154
WK CHANN. RAIHANN. MUSTAPHA ET AL.: "A randomized trial of silymarin for the treatment of non-alcoholic steatohepatitis", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol. 15, 2017, pages 1940 - 1949
FATTY LIVER AND ALCOHOLIC LIVER DISEASE GROUPS OF BRANCH OF HEPATOLOGY OF CHINESE MEDICAL ASSOCIATION: "Guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease", CHINESE JOURNAL OF HEPATOLOGY, vol. 14, 2006, pages 161 - 163
N. BELEMETSN. KOBYLIAKO. VIRCHENKO ET AL.: "Effects of polyphenol compounds melanin on NAFLD/NASH prevention", BIOMEDICINE AND PHARMACOTHERAPY, vol. 88, 2017, pages 267 - 276
N. KOBYLIAKL. ABENAVOLI: "The role of liver biopsy to assess non-alcoholic fatty liver disease", REVIEWS ON RECENT CLINICAL TRIALS, vol. 9, 2014, pages 159 - 169
G. MUSSOR. GAMBINOM. CASSADER ET AL.: "Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity", ANNALS OF MEDINCINE, vol. 43, 2011, pages 617 - 649, XP008166262, DOI: 10.3109/07853890.2010.518623
C. P. DAYO. F. W. JAMES: "Steatohepatitis: A tale of two ''hits", GASTROENTEROLOGY, vol. 114, no. 4, 1998, pages 842 - 845, XP005138793, DOI: 10.1016/S0016-5085(98)70599-2
C. POSTICJ. GIRARD: "Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 118, no. 3, 2008, pages 829 - 838, XP055580320, DOI: 10.1172/JCI34275
PZ LIK. HEJZ LI ET AL.: "The role of kupffer cells in hepatic diseases", MOLECULAR IMMUNOLOGY, vol. 85, 2017, pages 222 - 229, XP029972496, DOI: 10.1016/j.molimm.2017.02.018
R. SAFADIFM KONIKOFFM. MAHAMID ET AL.: "The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, no. 12, 2014, pages 2085 - 2091
PF SURAI.: "Silymarin as a natural antioxidant: an overview of the current evidence and perspectives", ANTIOXIDANTS (BASEL, vol. 4, 2015, pages 204 - 247, XP009502578, DOI: 10.3390/antiox4010204
A. FEDERICOM. DALLIOC. LOGUERCIO: "Silymarin/silybin and chronic liver disease: a marriage of many years", MOLECULES, vol. 22, 2017, pages 2
S. CLICHICID. OLTEANUA. FILIP ET AL.: "Beneficial effects of silymarin after the discontinuation of CC14-induced liver fibrosis", JOURNAL OF MEDICINAL FOOD, vol. 19, 2016, pages 789 - 797
ZHONGXIN LIU: "The efficacy of silymarin combined with pioglitazone in the treatment of 76 subjects of non-alcoholic fatty liver disease", CHINESE JOURNAL OF CLINICAL GASTROENTEROLOGY, vol. 24, no. 5, 2012, pages 288 - 290
SHELING LU: "Silymarin combined with metformin in the treatment of non-alcoholic fatty liver disease", JOURNAL OF MEDICAL FORUM, vol. 37, no. 4, 2016, pages 153 - 154
WK CHANN. RAIHANN. MUSTAPHA ET AL.: "A randomized trial of silymarin for the treatment of non-alcoholic steatohepatitis", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol. 15, 2017, pages 1940 - 1949
Attorney, Agent or Firm:
NANJING SITUO INTELLECTUAL PROPERTY AGENCY (GP) (CN)
Download PDF: